Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes
Authors:
- Michel DelforgeMDMichel Delforge
- Karen MacDonaldKMKaren MacDonald
- 12 February 2011
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 90 (6) , 655-666
Abstract
Transfusion dependency and iron overload are common among patients with myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with leukemic progression and shorter survival. Guidelines recommend iron chelation therapy to manage iron overload, however little is known about the chelation patterns in daily clinical practice. The objective of this multicenter, retrospective, cross-sectional, observational study was to evaluate iron status and its management in transfusion-dependent MDS patients. A total of 193 patient records from 29 centers were eligible for inclusion. Median patient age was 76, and median age at diagnosis of MDS was 74. Patients had received an average of 13.4 ± 7.6 RBC units in the past 4 months; 44% had received more than 50 units since their MDS diagnosis. Medium serum ferritin was 1,550 μg/L. Ninety patients (46.6%) received iron chelation therapy with either deferoxamine (41%), deferasirox (36%), and deferoxamine followed by deferasirox (23%). There were no statistically significant differences between chelated and nonchelated patients in terms of International Prognostic Scoring System (IPSS), French-American-British (FAB), and/or World Health Organization (WHO) status, though chelated patients had received more RBC transfusions (p = 0.014). Iron chelation therapy may be underutilized in transfusion-dependent patients. Undertreatment can be reduced by complementing sound clinical judgment with the generally accepted guidelines of a serum ferritin level >1,000 μg/L and/or two or more RBC transfusions per month for the past year; considering patients on the basis of their IPSS, FAB, and/or WHO status; and individually tailored treatment regimens. Prospective randomized trials are necessary to establish causally the efficacy of iron chelation therapy in MDS.Keywords
This publication has 38 references indexed in Scilit:
- Update on the therapy for myelodysplastic syndromeAmerican Journal of Hematology, 2009
- Consensus statement on iron overload in myelodysplastic syndromesAmerican Journal of Hematology, 2008
- Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromesCancer, 2008
- Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromesLeukemia Research, 2007
- Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic SyndromesJournal of Clinical Oncology, 2007
- The Myelodysplastic Syndromes: Diagnosis and TreatmentMayo Clinic Proceedings, 2006
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision MakingJournal of Clinical Oncology, 2005
- Myelodysplastic Syndromes — Coping with Ineffective HematopoiesisNew England Journal of Medicine, 2005
- MyelodysplasiaNew England Journal of Medicine, 1999
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982